{ 'indexed': {'date-parts': [[2024, 9, 10]], 'date-time': '2024-09-10T00:24:05Z', 'timestamp': 1725927845673},
'reference-count': 0,
'publisher': 'Kurdistan Higher Council of Medical Specialties',
'issue': '3',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2024, 9, 9]]},
'abstract': '<jats:p>ackground & objectives: The World Health Organization has identified COVID-19 as '
'a rapidly spreading global disease. Some antiviral drugs have shown promising efficacy in '
'treating COVID-19. This study aims to identify the effects of antiviral drugs and compare '
'them with other therapies in COVID-19 patients, while reviewing the clinical outcomes of '
'these treatments. Methods: This observational retrospective case study included 451 COVID-19 '
'patients, comprising 57.0% males and 43% females, conducted in Rizgari, Erbil, at Central '
'Emergency, Rozhawa Emergency, and Emirate Hospitals over one year from December 2020 to '
'December 2021. COVID-19 cases were confirmed using reverse transcriptase polymerase-chain '
'reaction (RT-PCR) assays, and treatment followed the WHO guidelines, involving antivirals '
'(Remdesivir, Favipiravir), broad-spectrum antibiotics (levofloxacin, azithromycin, '
'ceftriaxone, meropenem, imipenem), and supportive treatment with Becozym (Vitamins B1 + B2 + '
'B3 + B5 + B6). Data were recorded in the statistical department of the hospitals. Results: '
'The total age range of the 451 patients was 95 (18-113) with a mean ± SD of 59.408 ± 18.26 '
'years. The death rate was 22.39%. A majority of the survival patients were in the young age '
'group (95.1%), while the death rate was higher in the old age group (more than 75 years). The '
'death rate of patients treated with antiviral drug Remdesivir was 15.30%, while it was '
'37.93%, 73.45%, 15.25%, and 14.15% in patients on levofloxacin, ceftriaxone, meropenem, and '
'Becozyme, espectively. Logistic regression analysis did not show any role of treatments in '
'decreasing mortality. Conclusions: Significant differences were observed in clinical '
'outcomes; the majority of surviving patients were in the young age group, while older '
'COVID-19 patients had worse illnesses and treatment outcomes. Diabetes and hypertension were '
'significant predictors of COVID-19 mortality. Although Remdesivir treatment showed a '
'statistically significant association between survival and death cohorts, it was not '
'considered a predictor variable for survival. Antibiotics and supplement drugs like Becozyme '
'were also not considered predictors of survival for COVID-19 patients.</jats:p>',
'DOI': '10.56056/amj.2024.273',
'type': 'journal-article',
'created': {'date-parts': [[2024, 9, 9]], 'date-time': '2024-09-09T08:15:43Z', 'timestamp': 1725869743000},
'page': '17-25',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Antiviral drug treatment profiles and clinical outcomes of COVID-19 patients at public hospitals '
'in Erbil city.',
'prefix': '10.56056',
'volume': '9',
'author': [ { 'name': 'Trainee at Infection disease control department of public health, Kurdistan higher '
'council for medical specialties, Rizghary Hospital, Erbil city-Kurdistan '
'region/Iraq',
'sequence': 'first',
'affiliation': []},
{'given': 'Ronia Shawksat', 'family': 'Kawther', 'sequence': 'first', 'affiliation': []},
{'given': 'Sherzad Ali', 'family': 'Ismael', 'sequence': 'additional', 'affiliation': []},
{ 'name': 'Assistant Professor in Community Medicine,Chairman of Public Health council, '
'Kurdistan higher council for medical specialties, Erbil City-Kurdistan region/Iraq',
'sequence': 'additional',
'affiliation': []},
{'given': 'Maaroof Tahseen', 'family': 'Hassan', 'sequence': 'additional', 'affiliation': []},
{ 'name': 'Assistant Professor in Community Medicine. Program Director of Infection Disease '
'Control Department, Deputy President of Kurdistan higher council for medical '
'specialties, Erbil city-Kurdistan region/Iraq.',
'sequence': 'additional',
'affiliation': []}],
'member': '35163',
'published-online': {'date-parts': [[2024, 9, 9]]},
'container-title': 'Advanced medical journal',
'original-title': [],
'deposited': { 'date-parts': [[2024, 9, 9]],
'date-time': '2024-09-09T08:15:46Z',
'timestamp': 1725869746000},
'score': 1,
'resource': {'primary': {'URL': 'https://amj.khcms.edu.krd/index.php/main/article/view/473'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 9, 9]]},
'references-count': 0,
'journal-issue': { 'issue': '3',
'published-online': {'date-parts': [[2024, 9, 9]]},
'published-print': {'date-parts': [[2024, 9, 9]]}},
'URL': 'http://dx.doi.org/10.56056/amj.2024.273',
'relation': {},
'ISSN': ['2958-8979', '2957-3580'],
'subject': [],
'container-title-short': 'adv.med.j.',
'published': {'date-parts': [[2024, 9, 9]]}}
Late treatment is less effective
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.